Biopharma firm Swedish Orphan Biovitrum AB (Sobi) is implementing Kinaxis’ Maestro platform for end-to-end supply chain orchestration across its partner network. The implementation aims to enable data-driven supply chain decisions and accelerate delivery of critical therapies to patients with rare diseases.

Sobi operates in a complex field of healthcare, focusing biopharma development on rare diseases that currently lack approved treatments. Headquartered in Stockholm, Sweden, Sobi specialises in haematology, immunology and specialty care. The company delivers treatments to over 40,000 patients annually across 55 countries. Sobi’s operations require a high degree of speed, precision and visibility across its supply chain, as patients with rare conditions depend on its treatments.

Maestro capabilities in scenario planning, centralised data management and attribute-based planning will support Sobi in scaling operations and responding faster to potential disruptions to ensure supply of critical therapies.

“Kinaxis is well-regarded in the life sciences sector for its understanding of the unique complexities of supply chains that define this specific industry,” said Norbert Schoellhorn, vice president of global manufacturing and supply chain at Sobi. “We believe that Kinaxis will help us connect better with our partners, respond faster to change and deliver life-changing treatments to patients who can’t afford to wait.”

“Sobi’s work changes lives, and we’re proud to support them in delivering on that mission,” said Fabienne Cetre, executive vice president of EMEA at Kinaxis. “Sobi will utilise Maestro to unlock real-time collaboration and seamless execution in order to fast-track the delivery of critical therapies worldwide.”

Kinaxis is a supply chain technology partner for life sciences companies globally including Merck, Novartis, Bristol Myers Squibb, Cardinal Health, Boston Scientific, Servier and more. Deloitte Nordics will lead the implementation of Maestro.